Effect of Colchicine on Arterial Stiffness in Patients With Hypertension: The COlchicine HypERtENsion Trial (COHERENT)

Clicks: 16
ID: 332571
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #167 of 276 articles by views in european journal of preventive cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 276 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
AIM: This trial investigated whether colchicine, an anti-inflammatory treatment, affects cardiovascular structure and function, assessed by arterial stiffness, blood pressure and biochemistry, compared with placebo. METHODS: COHERENT was a randomized, double-blind, placebo-controlled trial of the effects of colchicine on arterial stiffness in adults with pharmacologically treated hypertension without cardiovascular disease. Eligible patients were randomized 1:1 to colchicine 0.5mg daily or placebo for six months. Assessment of arterial stiffness, echocardiography, and biomarker measurement were performed at baseline and six months. The primary endpoint was change in carotid-femoral pulse wave velocity (cfPWV). Secondary endpoints included change in blood pressure (BP), left ventricular mass index, as well as change in cardiac and inflammatory biomarkers. RESULTS: Of 183 screened, 150 were randomized (75 per group). Mean age was 64.5 (±8.0) years, 53 (35.3%) were female, and mean systolic blood pressure was 137.6 (±15.6) mmHg. At six months, cfPWV did not differ between groups (between-group difference in ΔcfPWV -0.1m/s, 95% CI: -0.5 to 0.3m/s, p=0.53). Office systolic BP decreased significantly more in the placebo group than in the colchicine group (between-group difference in Δoffice systolic BP 5.7 mmHg, 95% CI: 1.0 to 10.5 mmHg, p=0.018. hsCRP decreased significantly in the colchicine group compared with the placebo group (between-group difference in % change in hsCRP -39.8%, 95% CI: -59.1 to -11.4%, p=0.010). Left ventricular mass index or cardiac biomarkers did not differ between groups. CONCLUSIONS: Six months of colchicine did not affect arterial stiffness in pharmacologically treated hypertension without cardiovascular disease. Colchicine significantly decreased hsCRP.
Reference Key
openalex_W7222436862 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Adam Cadovius Femerling Langhoff, Niklas Dyrby Johansen, Katja Vu Bartholdy, Julie Borchsenius, Filip Soeskov Davidovski, Lise Witten Davodian, Maria Dons, Lisa Steen Duus, Caroline Espersen, Frederik Holme Fussing, Anne Marie Reimer Jensen, Mats Christian Højbjerg Lassen, Camilla Ikast Ottosen, Morten Sengeløv, Kristoffer Grundtvig Skaarup, Anne Bjerg Nielsen, Güldas Köse, Nino Emanuel Landler, Marat Yafasov, Jakob Øystein Simonsen, Daniel Modin, Marie Frimodt‐Møller, Tina Ken Schramm, Ahmad Sajadieh, Tor Biering‐Sørensen, Thomas A. Jepps
Journal european journal of preventive cardiology
Year 2026
DOI
10.1093/eurjpc/zwag527
URL
https://doi.org/10.1093/eurjpc/zwag527
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.